Pola-R-ICE: Results of the safety run-in phase of a phase III study comparing polatuzumab vedotin in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) with R-ICE alone in patients with refractory or relapsed diffuse large B-cell lymphoma

Laube, A; Fuhrmann, S; Van Heteren, P; Ziepert, M; Altmann, B; Davies, A; Greil, R; Garcia-Sancho, AM; Pellon, SGD; Schnetzke, U; De la Cruz Vicente, F; Hanel, M; Hess, G; Kohler, C; Masius, H; Glass, B ONCOL RES TREAT. 2022; 45(SUPPL 2): 83-84.

Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).

Aggarwal, RR; Rottey, S; Aparicio, A; Greil, R; Reimers, MA; Sandhu, SK; Zhang, YR; Salvati, M; Sadraei, NH J CLIN ONCOL. 2022; 40(6):

What is the management of resected cholangiocarcinoma in terms of intra- and postoperative status of tumor margins and lymph nodes? A current view.

Schlick, K; Neumayer, B; Neureiter, D; Expert Rev Gastroenterol Hepatol. 2022; 16(11-12):1019-1022

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC

Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Koeberle, D; Welslau, M; Sanoyan, DA; Maas, C; Uhlig, J; Fenchel, K; Greil, R; von der Heyde, E; Agocs, GR; Weide, R; Schwager, M; Reichenbach, F; Modest, DP; Fritsch, R ANTICANCER RES. 2022; 42(10): 4773-4785.

Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics.

Kusejko, K; Tschumi, N; Chaudron, SE; Nguyen, H; Battegay, M; Bernasconi, E; Boni, J; Huber, M; Calmy, A; Cavassini, M; Egle, A; Grabmeier-Pfistershammer, K; Haas, B; Hirsch, H; Klimkait, T; Ollinger, A; Perreau, M; Ramette, A; Flury, BB; Sarcletti, M; Scherrer, A; Schmid, P; Yerly, S; Zangerle, R; Gunthard, HF; Kouyos, RD JAIDS-J ACQ IMM DEF. 2022; 90(4): e4-e12.

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.

Gianni, L; Huang, CS; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Bianchini, G; Russo, S; Ciruelos, EM; Greil, R; Semiglazov, V; Colleoni, M; Kelly, C; Mariani, G; Del Mastro, L; Maffeis, I; Valagussa, P; Viale, G ANN ONCOL. 2022; 33(5): 534-543.

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18

Minichsdorfer, C; Fuereder, T; Leutner, M; Singer, CF; Kacerovsky-Strobl, S; Egle, D; Greil, R; Balic, M; Fitzal, F; Pfeiler, G; Frantal, S; Bartsch, R; Gnant, M ESMO OPEN. 2022; 7(2):

Randomized Clinical Study of Temporary Transvenous Phrenic Nerve Stimulation in Difficult-to-Wean Patients

Dres, M; de Abreu, MG; Merdji, H; Muller-Redetzky, H; Dellweg, D; Randerath, WJ; Mortaza, S; Jung, B; Bruells, C; Moerer, O; Scharffenberg, M; Jaber, S; Besset, S; Bitter, T; Geise, A; Heine, A; Malfertheiner, MV; Kortgen, A; Benzaquen, J; Nelson, T; Uhrig, A; Moenig, O; Meziani, F; Demoule, A; Similowski, T AM J RESP CRIT CARE. 2022; 205(10): 1169-1178.

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.

Kuemmel, S; Campone, M; Loirat, D; Lopez, RL; Beck, JT; De Laurentiis, M; Im, SA; Kim, SB; Kwong, A; Steger, GG; Adelantado, EZ; Duhoux, FP; Greil, R; Kuter, I; Lu, YS; Tibau, A; Özgüroğlu, M; Scholz, CW; Singer, CF; Vega, E; Wimberger, P; Zamagni, C; Couillebault, XM; Fan, L; Guerreiro, N; Mataraza, J; Sand-Dejmek, J; Chan, A; Clin Cancer Res. 2022; 28(1): 106-115.

An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes

Pleyer, L; Sekeres, MA LANCET HAEMATOL. 2022; 9(10): E714-E716.